Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, UBS Group Analyst Says

Charles River Laboratories International (NYSE:CRL) had its target price increased by investment analysts at UBS Group from $170.00 to $175.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. UBS Group’s price target indicates a potential downside of 0.15% from the company’s previous close.

Other analysts also recently issued research reports about the stock. TD Cowen cut their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a report on Friday, February 20th. Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a research report on Monday, December 1st. JPMorgan Chase & Co. raised their target price on Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Mizuho decreased their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Friday, February 20th. Finally, Bank of America upgraded Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, December 15th. Ten research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $203.57.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $175.26 on Wednesday. The business has a fifty day moving average price of $198.17 and a two-hundred day moving average price of $179.73. The stock has a market capitalization of $8.63 billion, a PE ratio of -59.21, a P/E/G ratio of 2.86 and a beta of 1.63. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. Charles River Laboratories International has a fifty-two week low of $91.86 and a fifty-two week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company had revenue of $994.23 million for the quarter, compared to analysts’ expectations of $986.98 million. During the same quarter last year, the business earned $2.66 earnings per share. Charles River Laboratories International’s revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, equities analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Hedge funds have recently made changes to their positions in the company. Tema Etfs LLC acquired a new position in shares of Charles River Laboratories International in the fourth quarter valued at approximately $26,000. Neo Ivy Capital Management acquired a new position in Charles River Laboratories International in the 2nd quarter valued at approximately $29,000. Rothschild Investment LLC raised its stake in shares of Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International during the third quarter worth $31,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth $42,000. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.